Invesco Ltd. Acquires Shares of 20,552 Maze Therapeutics, Inc. $MAZE

Key Points

• Invesco Ltd. has acquired 20,552 shares of Maze Therapeutics, Inc., valued at approximately $226,000, as part of its investment strategy.
• Research analysts have set a consensus price target of $26.33 for Maze Therapeutics, with ratings ranging from "Strong Buy" to "Buy."
• The stock of Maze Therapeutics is currently trading around $15.88, with a 52-week range between $6.71 and $19.19.

Invesco Ltd. acquired a new stake in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 20,552 shares of the company's stock, valued at approximately $226,000.

A number of other institutional investors have also recently bought and sold shares of the business. TRV GP IV LLC bought a new position in Maze Therapeutics in the 1st quarter valued at $66,874,000. Alphabet Inc. bought a new position in Maze Therapeutics in the 1st quarter valued at $26,561,000. General Catalyst Group Management LLC bought a new position in Maze Therapeutics in the 1st quarter valued at $11,405,000. TRV GP V LLC bought a new position in Maze Therapeutics in the 1st quarter valued at $10,468,000. Finally, Harvard Management Co. Inc. bought a new position in shares of Maze Therapeutics during the 1st quarter worth $7,019,000.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. BTIG Research assumed coverage on Maze Therapeutics in a research note on Tuesday, September 2nd. They set a "buy" rating and a $30.00 price target for the company. Wedbush started coverage on shares of Maze Therapeutics in a research note on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 target price for the company. HC Wainwright started coverage on shares of Maze Therapeutics in a research note on Wednesday, July 23rd. They issued a "buy" rating and a $34.00 target price for the company. Finally, Wall Street Zen upgraded shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Two research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to MarketBeat.com, Maze Therapeutics has an average rating of "Buy" and a consensus price target of $26.33.

Maze Therapeutics Stock Performance

Shares of NASDAQ MAZE opened at $15.88 on Monday. Maze Therapeutics, Inc. has a 52 week low of $6.71 and a 52 week high of $19.19. The business has a 50-day simple moving average of $14.55 and a two-hundred day simple moving average of $12.01.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.